BioNTech's Pumitamig Delivers Dose-Dependent Response in Lung Cancer, But ASCO Spotlight Highlights Competitive Gap
01.06.2026 - 19:41:58 | boerse-global.de
BioNTech wowed the ASCO Annual Meeting in Chicago with Phase 2 data for its bispecific antibody Pumitamig — yet investors pressed the sell button. The stock slid roughly 4% to €78.80, a sign that the market sees a gap between early promise and commercial reality. The Mainz-based biotech is betting its oncology pipeline can fill the void left by fading Covid vaccine revenue, but the path is narrowing.
The interim readout from the global Phase 2/3 ROSETTA Lung-02 study examined Pumitamig, a PD-L1xVEGF-A bispecific immunomodulator, combined with chemotherapy in previously untreated advanced non-small cell lung cancer (NSCLC). Among 40 evaluable patients with a median follow-up of nine months, the confirmed objective response rate hit 57.1% in non-squamous and 68.4% in squamous histology. The disease control rate reached 100%. A deeper look revealed a clear dose effect: at the lower 1,400 mg dose, responses climbed to 63.6% and 72.7%, respectively. That dose — selected jointly by BioNTech and partner Bristol Myers Squibb — is now moving into the pivotal Phase 3 portion. On safety, serious treatment-related adverse events occurred in 23.3% of patients, and the discontinuation rate stood at 9.3%, a profile analysts describe as manageable.
The real headwind sits on the ASCO podium itself. Summit Therapeutics and Akeso secured a plenary session — the conference's top billing — for Phase 3 data on Ivonescimab, their PD-1xVEGF candidate. Summit's HARMONi-6 trial showed a median overall survival advantage over Tislelizumab: 27.9 months versus 23.7 months in advanced squamous NSCLC. Analysts see no clear differentiation among the emerging PD-(L)1xVEGF class on efficacy or safety, and the consensus is that the market can support only two players long term — with Summit likely first to market. BioNTech’s Pumitamig may be the first global first-line candidate, but it remains in Phase 2, giving rivals a running start.
Should investors sell immediately? Or is it worth buying BioNTech?
Still, not all analysts are waiting. UBS upgraded the stock from Neutral to Buy shortly before the ASCO presentation, lifting its price target from $117 to $135. The bank pointed to the widening oncology pipeline beyond mRNA vaccines as a catalyst for re-rating. BioNTech's balance sheet supports the thesis: €16.8 billion in cash as of March 31, 2026, and full-year revenue guidance of €2.0 billion to €2.3 billion against an adjusted R&D spend of €2.2 billion to €2.5 billion. The first quarter underlined the transition — revenue of $118.1 million came with a net loss of $494.6 million, driven by heavy investment in clinical development.
Management is pairing clinical ambition with cost discipline. A share buyback program of up to $1 billion over twelve months is on the table. The company also plans to shutter production sites in Idar-Oberstein, Marburg, Singapore, and former CureVac locations, affecting roughly 1,860 jobs. Annual savings of around €500 million are targeted by 2029. The restructuring underscores the shift from pandemic-scale manufacturing to a leaner oncology-focused operation.
For the stock, which now trades 20% below its year-ago level and 23% off its 52-week high, the next catalyst hinges on execution. The Phase 3 part of ROSETTA Lung-02 is already recruiting. Whether Pumitamig can hold its own against Ivonescimab when mature data from both programs emerge will determine if BioNTech's oncology story gains real weight — or remains a promising footnote in a crowded field.
Ad
BioNTech Stock: New Analysis - 1 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
